文献速递肝肾功能剂量调整特殊人群用药

HRS-9231在肾功能不全患者中的药代动力学、消除及透析清除

Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.
PubMed 文献 · Clin Pharmacokinet · 2026-08-22

一项开放标签、非随机1期研究纳入40例不同肾功能受试者,单次静脉给予HRS-9231 0.05 mmol/kg。结果显示药物暴露随肾功能损害加重而增加,终末半衰期从正常1.7 h延长至重度7.2 h,透析可有效清除药物,未见肾源性系统性纤维化(NSF)病例,提示各程度肾功能不全可能无需调整剂量。

要点

  • HRS-9231暴露随肾功能损害加重而增加,重度损害AUC0-∞较正常高333%。
  • 终末半衰期从正常1.7 h延长至重度损害7.2 h,尿排泄累计超过85%。
  • 血液透析可有效清除HRS-9231,首次透析后血浆浓度降低84%。

核心结论

  • HRS-9231呈肾脏消除特征,清除率随肾功能损害程度加重而下降,血液透析可有效清除。
  • 各程度肾功能不全患者包括透析患者中未发现新的安全性信号或NSF病例,支持可能无需调整剂量。

研究设计与样本

  • 开放标签、非随机1期研究,40例受试者按肾功能分为正常、轻度、中度、重度损害及终末期肾病(ESRD)五组。
  • 单次静脉给予HRS-9231 0.05 mmol/kg,进行96-120 h密集药代动力学采样,ESRD患者给药后接受血液透析并同步采集血浆和透析液。
  • 长期钆消除和安全性随访至6个月。

主要发现

  • AUC0-∞几何均值在轻度、中度、重度损害组分别较正常组高35%、104%、333%。
  • 平均终末半衰期从正常1.7 h延长至重度损害7.2 h,各队列累计尿排泄均超过85%。
  • ESRD患者首次透析后血浆浓度降低84%,三次透析后浓度低于定量下限。
  • 钆水平随时间下降,6个月内回到未暴露参考范围。
  • 6个月随访期间未观察到NSF或相关症状病例。

关键数值与推荐

  • 单次静脉剂量为0.05 mmol/kg。
  • AUC0-∞在轻度、中度、重度损害组分别较正常升高35%、104%、333%。
  • 终末半衰期正常1.7 h,重度损害7.2 h。
  • 累计尿排泄各队列超过85%,首次透析后血浆浓度降低84%。

临床怎么用

  • 基于药代动力学数据,各程度肾功能不全患者包括透析患者可能无需调整HRS-9231剂量。
  • ESRD患者接受血液透析可有效清除HRS-9231,三次透析后血浆浓度低于定量下限。
  • 研究未发现新的安全性信号或NSF病例,但样本量小不足以确切评估NSF风险。

局限性

  • 每组样本量有限,研究未针对NSF风险进行统计效力设计。
  • 鉴于大环状钆对比剂预期NSF发生率低且样本量小,无法确切评估NSF风险。
  • 开放标签、非随机设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to characterize the pharmacokinetics (PK), elimination and dialysability of HRS‑9231, a novel macrocyclic gadolinium‑based contrast agent, in individuals with varying degrees of renal impairment, including those requiring hemodialysis. METHODS: In this open‑label, non‑randomized, Phase 1 study, 40 participants were stratified into five cohorts based on renal function: normal, mild, moderate, severe impairment, and end‑stage renal disease (ESRD). All received a single intravenous dose of HRS‑9231 (0.05 mmol/kg). Intensive PK sampling was performed over 96-120 h. End‑stage renal disease patients underwent hemodialysis sessions post‑dose, with concurrent plasma and dialysate collection. Long‑term gadolinium elimination and safety were monitored for up to 6 months. RESULTS: Systemic exposure to HRS‑9231 increased with renal impairment severity: geometric mean area under the plasma concentration versus time curve from zero to infinity (AUC0‑∞) was 35%, 104%, and 333% higher in mild, moderate, and severe impairment cohorts, respectively, versus normal function. Mean terminal half‑life prolonged from 1.7 h (normal) to 7.2 h (severe). Cumulative urinary excretion exceeded 85% across cohorts. In ESRD patients, hemodialysis efficiently removed HRS‑9231, with an 84% reduction in plasma concentration after the first session and concentrations falling below the limit of quantitation after three sessions. Gadolinium levels declined over time, returning to the unexposed reference range within 6 months. During the 6‑month follow‑up, no cases of nephrogenic systemic fibrosis (NSF) or related symptoms were observed. Given the low expected incidence of NSF with macrocyclic GBCAs and the limited sample size per cohort, this study was not statistically powered to definitively assess NSF risk. Nonetheless, the absence of NSF cases in this at‑risk population provides supportive evidence consistent with the established safety profile of macrocyclic GBCAs. CONCLUSIONS: HRS‑9231 exhibits a PK profile consistent with renal elimination. Its clearance decreases proportionally with renal impairment, and it is effectively cleared by hemodialysis. HRS‑9231 was generally well tolerated in this small cohort of patients with varying degrees of renal impairment, including those on hemodialysis. No new safety signals or NSF cases were identified. These findings, together with the PK data, support that dose adjustment is unlikely to be necessary for patients with any degree of renal impairment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06657560.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Han Q, Zhang R, He Y, et al. Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment. Clin Pharmacokinet. 2026. PMID: 42631820. doi:10.1007/s40262-026-01688-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。